Bioamber (NYSE: BIOA) reported Q4 EPS of ($0.20), $0.19 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $308 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Bioamber (BIOA) click here.